Patents Assigned to Novartis AG
  • Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
    Patent number: 11613543
    Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: March 28, 2023
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Julien Lorber, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • BCMA chimeric antigen receptors and uses thereof
    Patent number: 11608382
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 21, 2023
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • Injector device
    Patent number: 11607486
    Abstract: The invention concerns an injector device (100), comprising access means (110, 115) configured to selectively allow and prevent a cartridge (120) storing a pharmaceutical product (122) from being removed from the injector device (100), a self-test unit (130) configured to cause a self-test of at least one of an electronic component and an electronic assembly of the injector device (100), and a control unit (140) configured to control the access means (110, 115) to allow the cartridge (120) to be removed from the injector device (100) in case the self-test has failed.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: March 21, 2023
    Assignee: Novartis AG
    Inventors: Alain Schmidlin, Mario Iobbi, Erich Studer, Andrew Bryant, Chinmay Deodhar, Rajan Patel
  • Crystalline form of LNP023
    Patent number: 11603363
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: March 14, 2023
    Assignee: Novartis AG
    Inventors: Zichen Jia, Philipp Lustenberger, Marie Meyer, Massimo Moratto
  • PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF
    Publication number: 20230074486
    Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
    Type: Application
    Filed: November 1, 2022
    Publication date: March 9, 2023
    Applicants: Genentech, Inc., Novartis AG
    Inventor: Charles M. WINTER
  • Compounds and compositions for treating conditions associated with NLRP activity
    Patent number: 11597706
    Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: March 7, 2023
    Assignee: Novartis AG
    Inventors: Gary Glick, Shomir Ghosh, William R. Roush
  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 11597733
    Abstract: The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: March 7, 2023
    Assignee: Novartis AG
    Inventors: Nicole Alice Blaquiere, Richard Yichong Huang, Thomas Martin Kirrane, Jr., Andreas Kordikowski, Anne-Catherine Mata, Christopher Ronald Sarko, Benjamin Robert Taft, Grace Lamprecht Waldron, Fumiaki Yokokawa, Tingying Zhu
  • Specific sites for modifying antibodies to make immunoconjugates
    Patent number: 11596695
    Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: March 7, 2023
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Weijia Ou, Tetsuo Uno
  • Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same
    Patent number: 11590158
    Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: February 28, 2023
    Assignee: Novartis AG
    Inventors: Christoph Bucher, Dietmar Flubacher, Jeremiah Douglas Foutch, Malay Ghosh, Johannes Franz Kluge, Zaixing Li, Cale Ry McAlister, Liladhar Murlidhar Waykole, Jens Sören Worthmann, Tingying Zhu
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 11591404
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: February 28, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION
    Publication number: 20230049217
    Abstract: The present disclosure provides compositions and methods of restoring or enhancing visual function in an individual by administering to the individual a pharmaceutical composition comprising a recombinant adeno-associated viral (rAAV) vector having a polynucleotide sequence that encodes a medium wavelength cone opsin (MW-opsin). The MW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.
    Type: Application
    Filed: May 18, 2022
    Publication date: February 16, 2023
    Applicant: Novartis AG
    Inventors: Karen I. Guerin, Robert M. Kotin, Eric Pastor, Xiaozhi Ren, Sharon Young
  • Stable and soluble antibodies inhibiting TNF?
    Patent number: 11578123
    Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: February 14, 2023
    Assignee: Novartis AG
    Inventors: Leonardo Borras, Tea Gunde, David Urech
  • Chemical process for preparing phenylpiperidinyl indole derivatives
    Patent number: 11578053
    Abstract: The present invention relates to a method of synthesizing a compound of formula (I) also referred to as 4-(((2S,4S)-(4-ethoxy-1-(((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid, or a pharmaceutically acceptable salt thereof, and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: February 14, 2023
    Assignee: Novartis AG
    Inventors: Peng Fu, Yu Gai, Feng Gao, Weiyong Kong, Yadong Lu, Zhongcheng Min, Shaofeng Rong, Chutian Shu, Can Wang, Ruidong Wang, Jibin Zhao, Xianglin Zhao, Yi Zhao, Jianguang Zhou, Benjamin Martin
  • Regulatable chimeric antigen receptor
    Patent number: 11578130
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 14, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11566022
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders, including hemoglobinopathies, sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 31, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Dales, John Ryan Kerrigan, Philip Lam, Hasnain Ahmed Malik, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Ting
  • METHOD OF DERIVING A VALUE FOR PERCENT BIOMARKER POSITIVITY FOR SELECTED CELLS PRESENT IN A FIELD OF VIEW
    Publication number: 20230017087
    Abstract: The invention relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 19, 2023
    Applicant: Novartis AG
    Inventors: Naveen DAKAPPAGARI, Jennifer BORDEAUX, Thai TRAN, Ju Young KIM
  • Injection device and injection solution transferring system
    Patent number: 11554215
    Abstract: An injection device (10) comprises an injection solution receptacle (30) and a plunger (70) at least a portion of which is slidably received in the injection solution receptacle (30), wherein the plunger (70) is displaceable relative to the injection solution receptacle (30) in a distal direction in order to expel an injection solution contained in the injection solution receptacle (30) from the injection solution receptacle (30). A first plunger stop mechanism (140) is adapted to stop a displacement of the plunger (70) relative to the injection solution receptacle (30) in the distal direction at a first dosing position (P1).
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 17, 2023
    Assignee: Novartis AG
    Inventors: Nicholas Lee Hawson, Martin Murphy, Frederick William Hamlin, Christophe Royer, Dominic Lloyd-Lucas, Tony Bedford, Andrew Gow, Dave Harris, Duncan Aleck Bishop, Matthew Garwood, Matthew Murchie, Lasse Mogensen
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11548865
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 10, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • Crystalline forms of a triazolopyrimidine compound
    Patent number: 11548897
    Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: January 10, 2023
    Assignee: Novartis AG
    Inventors: Ying Huang, Bo Liu, Liang Mao, Long Wang, Liladhar Murlidhar Waykole, Lijun Zhang
  • Cell secreted minibodies and uses thereof
    Patent number: 11549099
    Abstract: The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: January 10, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Laura Alexandra Johnson, Danielle Cook